Monalizumab Biosimilar (NKG2A / CD94 Reference Antibody)
Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A) . Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC) .
Product Specifications
Target
Monalizumab Biosimilar (Anti-NKG2A / CD94 Reference Antibody)
Clonality
Monoclonal
Conjugation
Unconjugated
Field of Research
Immunology & Inflammation
Purity
>98%
Storage Conditions
Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
lis 250 2 mL
Anti-Listeria all Antigens magnetic nanoparticles, 250 nm
Sign In for Pricing
View Details 
K4870404 1.0 µg DNA
Snrpe sgRNA CRISPR Lentivector (Mouse) (Target 3)
Sign In for Pricing
View Details